News

Fasika Woreta, MD, discussed the Roman-Barnes lecture and the cornea care landscape ahead of the National Medical Association meeting.

Ore-ofe O. Adesina, MD, described the advances in diagnostics and therapeutics in Neuro-Ophthalmology at the National Medical Association annual meeting.

Statin use was linked with increased glaucoma likelihood in the overall adult All of Us Research Program population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals from 60 to 69 years old.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The nonprofit Prevent Blindness recognised the awareness month with a slate of resources

The company is developing ixoberogene soroparvovec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.

As a medical student at the University of Miami Miller School of Medicine, Ashlyn Anzu Gary landed the unique opportunity to help launch an interdisciplinary clinical research program exploring hypnotherapy as a treatment for people with chronic eye pain.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated software analysis to increase screening rates.

According to the company, VCN-01, its lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. The FDA had previously granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry at EyeCon.

Consultant ophthalmologist Christiana Dinah, BSc, MB BS, MRes, presented research findings on retinal vein occlusion in the United Kingdom

The microRNA(miR)-17-92 cluster is known to play an important role in cell signaling, but its specific functions in the eye are not well understood. The researchers’ focus lies in gaining insights into the mechanisms of miR-17-92 cluster members and their effects on IOP.

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.

In a press release, Roche noted that up to 60% of patients were able to extend treatment intervals to 3 or 4 months

Prevent Blindness provides opportunities for awareness and action in support of new legislation to provide much-needed funding for children’s vision programs in the United States.

Nebraska Medicine taps technology for use in clinics.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

The EMA issued a designation for the small molecule photoswitch, which targets inherited retinal diseases including retinitis pigmentosa

Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorization for the treatment of dry eye disease in the European Union.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

The study helped identify predisposing factors for severe SANS in astronauts.

According to the company, its ViaLase Laser combines state-of-the-art femtosecond laser technology with micron-level image guidance to deliver the first femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT), marking a shift in glaucoma care.

Femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) received approval for patients in Europe with primary open-angle glaucoma

iStent implantations increased sharply, whereas trabeculectomies saw a decline.